Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.31
$0.40
50-Day Range
$0.33
$0.33
52-Week Range
$0.25
$1.19
Volume
4.12 million shs
Average Volume
173,401 shs
Market Capitalization
$17.03 million
P/E Ratio
N/A
Dividend Yield
123.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENZ Stock News Headlines

Battery Ventures Completes Take-Private of Enzo Biochem
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of customer deposits as Americans rush into a new form of money… That’s just been authorized under President Trump’s highly controversial new law, S.1582.tc pixel
ENZB - Enzo Biochem Inc Dividends - Morningstar
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings results on Monday, March, 17th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter. The medical research company had revenue of $7.33 million for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative trailing twelve-month return on equity of 7.96%.

Enzo Biochem's top institutional shareholders include RBF Capital LLC (0.29%). Insiders that own company stock include James G Wolf and Hamid Erfanian.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Last Earnings
3/17/2025
Today
9/22/2025
Fiscal Year End
7/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NYSE:ENZ
CIK
316253
Employees
520
Year Founded
1976

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.08 million
Net Margins
-75.34%
Pretax Margin
-23.79%
Return on Equity
-7.96%
Return on Assets
-5.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.55
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$29.09 million
Price / Sales
0.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
52,403,000
Free Float
46,288,000
Market Cap
$17.03 million
Optionable
Optionable
Beta
1.19

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:ENZ) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners